Introduction
Deafness, which refers to varying degrees of hearing loss, is one of the most common sensory disorders. Although there are many causes of deafness, genetic factors account for approximately 50-60% of cases (1) . The GJB2 gene is the most frequently mutated gene in cases of hereditary hearing loss, but the mutation spectrum varies among ethnic groups. For example, among Caucasians the most common GJB2 mutation is c.35delG, with a carrier frequency of 2-4% (2) . However, c.235delC is most frequently observed among Asians, with an allele frequency in the hearing impaired ranging from 5-22% (3) (4) (5) . Notably, p.V37I (c.109G>A) also has a high incidence in Asia, with a frequency of 8.5% in Thailand (6), 1.75% in Japan (7) , and 6.2% in China (8) in patients with hearing loss.
The p.V37I mutation was first identified as a polymorphism because it was present on one chromosome in normal individuals but not in the deaf (9) . However, compound heterozygous mutations (i.e., p.V37I and R143W heterozygous mutations) were later observed in a Japanese family that exhibited deafness (10) . R143W was later confirmed to cause recessive nonsyndromic
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sensorineural deafness (11) . A study of the p.V37I genotype of GJB2, a genetic risk factor for permanent childhood hearing impairment, revealed that the mutation was closely related to late-onset hearing loss in Chinese children (8) . Many studies (12) (13) (14) have also found that the mutation is more prevalent in patients than in control subjects; it has therefore been classified as a recessive missense mutation. GJB2 has two modes of inheritance, i.e., dominant and recessive, that often manifest as syndromic and nonsyndromic deafness, respectively. Most individuals with GJB2-associated deafness are nonsyndromic and exhibit autosomal recessive inheritance (15); GJB2-associated deafness was initially described as bilateral, severe-to-profound, autosomal-recessive, nonprogressive, sensorineural hearing loss (16, 17) . However, there is growing recognition of a wide range of phenotypes associated with GJB2 mutations, ranging in severity from mild to profound hearing loss with varying degrees of progression (18, 19) . Given that p.V37I is associated with mild and progressive hearing loss, clinical identification of affected individuals is vital (20, 21) .
Recent studies on p.V37I have focused on the incidence of p.V37I (6) (7) (8) and the hearing status of individuals with a p.V37I homozygous mutation or heterozygous mutation (Table 1) . Subjects in those studies generally had a mean age over 6 except those in the study by Huang et al. (25) , where subjects had a mean age of 0-3 months. Nonetheless, the principle was the same: subjects were initially the hearing impaired; GJB2 sequencing was performed as part of genetic testing, and results suggested that p.V37Iassociated hearing loss was mild to moderate or diverse hearing loss (19, (22) (23) (24) (25) (26) 
Kim et al. Patients with HL and an average age of 13.7 ± 4.5.
Children under the age of 15 with HL (n = 103). Five carried the p.V37I variant of GJB2.
945 subjects with HL and a mean age over 6. Twenty-five subjects were identified as p.V37I homozygous.
Of a total of 300 infants ages 0-3 months diagnosed with HL, 26 exhibited the p.V37I mutation of GJB2.
A large cohort of 152 Moroccan families with HL.
Conclusion
The p.V37I homozygous mutation is associated with mild to moderate hearing loss.
Revealed a unique GJB2 mutation spectrum in Chinese patients with HL. The p.V37I mutation may be pathogenic, with an allele frequency of 6.7%.
The p.V37I variant of GJB2 contributes to the pathogenesis of mild HL and may justify sequencing of GJB2 in Korean patients with mild to moderate hearing loss.
The homozygous p.V37I variant of GJB2 is associated with diverse hearing phenotypes
The p.V37I mutation of GJB2 is also strongly correlated with SNHL in infants, whose hearing pheno-types ranged from mild to profound. In addition, 69.6% of p.V37I carriers exhibit mild to moderate HL, indicating that even patients with mild or moderate HL must be tested for GJB2.
GJB2 mutations may play a role in 43.42% of the Moroccan patients diagnosed with HL. p.V37I had an allele frequency of 3.29%. This mutation was homozygous and compound heterozygous in patients with moderate HI. The age at first visit was 3-6 months for 12 subjects, younger than 3 months for 3 subjects, and 6-12 months for 5 subjects.
Genetic testing
Three different sequence variants were identified in the coding region of GJB2 (Figure 1 ). The most common mutation was the c.235delC/p.V37I compound p.V37I had a frequency of 4.04%. However, no study has examined the clinical significance of the p.V37I compound heterozygous mutation in deafness (27) . This was addressed in the present study by examining the clinical characteristics of children with this mutation.
Materials and Methods
Parents provided written, informed consent for subjects to participate in this study. The protocol was in accordance with the Declaration of Helsinki principles and was approved by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University. Inclusion criteria were as follows: 1 of the 4 mutations in GJB2 identified in screening for deafness genes and the presence of the p.V37I mutation according to sequencing. Exclusion criteria were as follows: carriers of GJB3 c.538C>T, SLC26A4 c.IVS7-2A>G or c.2168A>G, or mitochondrial 12S rRNA m.1555A>G or m.1494C>T mutations; GJB2 homozygous or compound heterozygous mutations; familial segregation of hearing loss in an autosomal dominant, maternally transmitted, or X-linked manner; and individuals with syndromic hearing loss, conductive deafness, or secretory otitis media.
Subject recruitment

Clinical evaluation
The following demographic information was collected for each patient: sex, date of birth and birth history, history of maternal pregnancy, family history, date of initial otolaryngological consultation, and major comorbidities. All subjects were Chinese.
DNA analysis
Genomic DNA was extracted from 2 mL of whole blood from each patient, using the Blood DNA kit (Tiangen Biotech, Beijing, China). All exons and flanking splice sites of GJB2 were screened for mutations using PCR amplification and bidirectional sequencing (22) . 
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Audiological evaluation
Clinical examination and medical history ruled out the involvement of environmental factors in the hearing loss of the 20 subjects and did not reveal clinical evidence of syndromic features. No pre-or postnatal risk factors were identified. Twelve subjects were referred for hearing screening, including two subjects who were referred for unilateral screening (right ear). Eight subjects passed the screening. Tympanometry revealed normal tympanic membranes in 18 subjects. Audiological results were obtained for 18 subjects; 2 subjects were lost to followup. Of the 18 subjects, 9 had mild hearing loss and 5 had moderate hearing loss while 4 had normal hearing (in the better ear). The 2 subjects who were lost to follow-up passed the hearing screening and were female ( Table 2 ).
Relationship between mutations and patient characteristics
The age at first visit, sex, mutation, hearing screening, and degree of hearing loss were compared among subjects ( Table 3 ). Most patients had their first visit at the age of 3-6 months (7 of those had the c.235delC/ p.V37I compound heterozygous mutation and 5 had the c.299delAT/p.V37I compound heterozygous mutation). However, only 1 subject had the c.176del16/p.V37I mutation, and the subject's first visit was after the age of 6 months. The age at first visit was most often 3-6 months for subjects who passed the hearing screening (n = 6). A point worth noting is that 3 subjects who were referred for the hearing screening test were under the age of 3 months at first visit. The degree of hearing loss was determined for 18 subjects; mild hearing loss occurred irrespective of age at first visit.
Hearing screening test results were examined with respect to GJB2 mutations (Table 4 ). Among subjects with the c.235delC/p.V37I compound heterozygous mutation, 7 were referred for the hearing screening test and 5 passed. Among subjects with the c.299delAT/ p.V37I mutation, 4 were referred for testing and 3 passed. One subject with the c.176del16/p.V37I mutation was referred for testing. The degree of hearing loss in subjects was examined with respect to GJB2 compound heterozygous mutations ( Table 5 ). Among subjects with the c.235delC/p.V37I compound heterozygous mutation, 5 had mild hearing loss and 2 had moderate hearing loss while 3 had normal hearing. Among subjects with the c.299delAT/p.V37I mutation, 3 had mild hearing loss and 3 had moderate hearing loss while 1 had normal hearing. One subject with the c.176del16/p.V37I mutation exhibited mild hearing loss.
Discussion
Hearing impairment is a common disorder with a major impact on public health. Many factors can cause deafness, but genetics account for approximately 50-60% of cases (1) . GJB2 is the gene that is most frequently implicated in hearing impairment, and its normal expression in the inner ear is required for normal development and signal transduction between inner ear sensory cells and supporting cells (28) . The GJB2 gene mutation spectrum varies according to ethnicity. For example, the most common GJB2 mutation among Caucasians is c.35delG (2), whereas c.235delC is the most prevalent mutation among Asians (3) (4) (5) . The spectrum of GJB2 gene mutations associated with autosomal recessive nonsyndromic hearing loss is continually expanding (29) .
The p.V37I (c.109G>A) mutation is highly prevalent in Asia (6) (7) (8) 27) , but its pathogenicity is debated. Up to 6% of Han Chinese are carriers of p.V37I, suggesting that there are over 4 million people with p.V37I homozygous mutations in China (24) . A previous study reported the occurrence of a compound heterozygous mutation (p.V37I and R143W) in a Japanese family with hearing impairment (10) . R143W has been confirmed to cause recessive non-syndromic sensorineural deafness (11) . However, p.V37I is also thought to be linked to hearing impairment, as it is found more often in patients than in normal controls (10, (12) (13) (14) 30) . Therefore, p.V37I is classified as a recessive missense gene.
First, studies on p.V37I have focused on the incidence of p.V37I (6) (7) (8) . Recent studies have increasingly revealed the hearing status of individuals with p.V37I homozygous mutation or heterozygous mutation ( Table 1 ). In most of those studies, subjects generally had a mean age over 6 except those in the study by Huang et al. (25) , where subjects had a mean age of 0-3 months. Nonetheless, the principle was the same: subjects were initially the hearing impaired, GJB2 sequencing was performed as part of genetic testing, and results suggested that p.V37I-associated hearing loss was mild to moderate or diverse hearing loss (19, (22) (23) (24) (25) (26) . In China, newborn screening for deafness genes was first instituted in Beijing, in 2012, and newborns are screened for 9 loci in 4 genes, including GJB2 c.235delC, c.299delAT, c.176dell6, and c.35delG; GJB3 c.538C>T; SLC26A4 c.IVS7-2A>G and c.2168A>G; and mitochondrial 12S rRNA m.1555A>G and m.1494C>T. Numerous newborns have been referred for screening for deafness genes. In the process of genetic counseling and clinical diagnosis, a large number of infants with a single locus mutation in GJB2 have been identified. In a preliminary study, the current authors screened 915 newborns for 4 GJB2 mutant alleles, i.e., c.235delC, c.299delAT, c.176del16, c.35delG, and GJB2 sequencing revealed that p.V37I had a frequency of 4.04%. However, no study has examined the clinical significance of the p.V37I compound heterozygous mutation in deafness (27) . This was addressed in the present study by examining the clinical characteristics of children with this mutation.
The present study examined the rate of GJB2 compound mutations, i.e., p.V37I concurrent with either c.235delC, c.299delAT, c.176del16, or c.35delG, in Chinese children under the age of 5. Results revealed that more males than females were compound heterozygotes. The most common compound heterozygous mutation was c.235delC/p.V37I, which was detected in 12 of 20 subjects, while no subjects had the c.35delG mutation. This is consistent with previous findings that c.235delC is common among Chinese whereas c.35delG is rare (2) (3) (4) (5) .
More subjects were referred for the hearing screening test than subjects who passed. Of those who BioScience Trends Advance Publication P6 underwent screening, only 1 had normal hearing; the others exhibited mild to moderate hearing loss. Of those that passed the hearing screening test and were followed up, half had mild hearing loss. A study found that biallelic mutations in GJB2 are a rare occurrence among newborns that pass the screening test if p.V37I is screened for (31) . The inability to identify an infant who is most likely deaf based on genetic testing may be attributable to technical limitations or to the late onset of hearing loss. This would contradict the contention that the hearing loss caused by GJB2 mutations is usually congenital, moderate to profound, and nonprogressive (16, 17) .
The p.V37I mutation is associated with mild to moderate hearing loss (30) (31) (32) , which was corroborated by the current findings. Biallelic truncating mutations (i.e., frameshift and nonsense mutations such as c.35delG, c.235delC, and c.167delT) are detected more frequently in individuals with severe to profound hearing loss, whereas biallelic amino acid substitutions (missense mutations; e.g., p.V37I) occur more frequently in individuals with mild to moderate hearing loss. Mutations in the GJB6 gene should be considered when infants present with hearing impairment since these mutations are significantly correlated with GJB2 mutations in individuals with nonsyndromic sensorineural hearing loss (33).
Conclusion
The GJB2 c.235delC/p.V37I compound heterozygous mutation was the mutation that was detected most often in the Chinese children in this study, and that mutation was mainly associated with mild to moderate hearing loss. Therefore, children need to undergo hearing screening or screening for the GJB2 p.V37I mutation. Although the current findings need to be verified in a larger sample, they nonetheless provide a reference for clinical diagnosis and treatment of hearing loss in children.
